English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Significance This paper discusses the successes and failures of tyrosine kinase inhibitors in treating cancer, and why we believe targeted immunotherapy may provide more durable remissions. Tyrosine kinases are central to tumor development and progression. Since we originally demonstrated specific inhibition of tyrosine kinases, with minimal toxicity, a large number of tyrosine kinase inhibitors—both small molecules and antibodies—have entered the clinic. Nonetheless, tumors are heterogeneous and highly mutable, and they eventually bypass tyrosine kinase inhibition. The immune system has the ability to seek and destroy tumor cells. Tumors avoid detection by the immune system, so the goal is to reinstate immune surveillance against the tumor.

My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer